Safety profile of Helicobacter pylori eradication treatments: literature review and updated data of the European Registry on Helicobacter pylori management (Hp-EuReg)

References

• Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. doi: 10.1136/gutjnl-2015-309252
   PubMed Web of Science ®Google Scholar
• Gravina AG, Priadko K, Ciamarra P, et al. Extra-gastric manifestations of Helicobacter pylori infection. J Clin Med. 2020;9(12):3887. doi: 10.3390/jcm9123887
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Alcedo J, Amador J, et al. V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 2022;45(5):392–417. doi: 10.1016/j.gastrohep.2021.07.011
   PubMedGoogle Scholar
• Gisbert JP, Pérez-Aisa A, Castro-Fernández M, et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liv Dis. 2010;42(4):287–290. doi: 10.1016/j.dld.2009.06.007
   Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239. doi: 10.1038/ajg.2016.563
   PubMed Web of Science ®Google Scholar
• Nyssen OP, Perez-Aisa A, Tepes B, et al. Adverse event profile during the treatment of helicobacter pylori: a real-world experience of 22,000 patients from the European registry on H. pylori management (Hp-EuReg). Am J Gastroenterol. 2021;116(6):1220–1229. doi: 10.14309/ajg.0000000000001246
   PubMed Web of Science ®Google Scholar
• Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013. doi:10.1002/14651858.CD008337.pub2
   Web of Science ®Google Scholar
• Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther. 2015;41(6):581–589. doi: 10.1111/apt.13069
   PubMed Web of Science ®Google Scholar
• Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016;2016(6). doi: 10.1002/14651858.CD009034.pub2
   PubMedGoogle Scholar
• Mori H, Suzuki H, Matsuzaki J, et al. Antibiotic resistance and gyrA mutation affect the efficacy of 10‐day sitafloxacin‐metronidazole‐esomeprazole therapy for Helicobacter pylori in penicillin allergic patients. United Eur Gastroenterol J. 2017;5(6):796–804. doi: 10.1177/2050640616688995
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762. doi: 10.1136/gutjnl-2022-327745
   Web of Science ®Google Scholar
• McNicholl AG, O’Morain CA, Megraud F, et al. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg). Helicobacter. 2019;24(5):24. doi: 10.1111/hel.12630
   Web of Science ®Google Scholar
• Nyssen OP, Moreira L, García-Morales N, et al. European Registry on Helicobacter pylori Management (Hp-EuReg): most relevant results for clinical practice. Front Gastroenterol. 2022;1:1. doi: 10.3389/fgstr.2022.965982
   Google Scholar
• Bi H, Chen X, Chen Y, et al. Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. Chin Med J (Engl). 2022;135(14):1707–1715. doi: 10.1097/CM9.0000000000002289
   PubMed Web of Science ®Google Scholar
• Shao Q, Yu X, Yu M, et al. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: a single‐center, prospective, open‐label, randomized‐controlled trial. Helicobacter. 2022;27(2):27. doi: 10.1111/hel.12876
   Web of Science ®Google Scholar
• Zhu Y-J, Zhang Y, Wang T-Y, et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol. 2020;13:175628482093711. doi: 10.1177/1756284820937115
   Web of Science ®Google Scholar
• Chey WD, Mégraud F, Laine L, et al. Vonoprazan Triple and dual therapy for Helicobacter pylori Infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608–619. doi: 10.1053/j.gastro.2022.05.055
   PubMed Web of Science ®Google Scholar
• Liu L, Li F, Shi H, et al. The efficacy and safety of Vonoprazan and amoxicillin dual therapy for Helicobacter pylori infection: a systematic review and network meta-analysis. Antibiotics. 2023;12(2):346. doi: 10.3390/antibiotics12020346
   Google Scholar
• Fernández-Salazar L, Campillo A, Rodrigo L, et al. Effectiveness and safety of high-dose dual therapy: results of the European registry on the management of helicobacterpylori infection (hp-EuReg). J Clin Med. 2022;11(12):3544. doi: 10.3390/jcm11123544
   PubMed Web of Science ®Google Scholar
• Hawkey C, Avery A, Coupland CAC, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet. 2022;400(10363):1597–1606. doi: 10.1016/S0140-6736(22)01843-8
   PubMed Web of Science ®Google Scholar
• Liou J-M, Lee Y-C, El-Omar EM, et al. Efficacy and Long-term safety of H. pylori eradication for gastric cancer prevention. Cancers (Basel). 2019;11(5):593. doi: 10.3390/cancers11050593
   PubMed Web of Science ®Google Scholar
• Grgov S, Tasic T, Radovanovic-Dinic B, et al. Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study. VSP. 2016;73(11):1044–1049. doi: 10.2298/VSP150415127G
   Google Scholar
• Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46(2):106–114. doi: 10.1111/apt.14130
   PubMed Web of Science ®Google Scholar
• Mahmoud A, Abuelazm M, Ahmed AAS, et al. Efficacy and safety of polaprezinc-based therapy versus the standard triple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14(19):4126. doi: 10.3390/nu14194126
   PubMed Web of Science ®Google Scholar
• Luther J, Higgins PDR, Schoenfeld PS, et al. empiric quadruple vs. triple Therapy for Primary Treatment of Helicobacter pylori Infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65–73. doi: 10.1038/ajg.2009.508
   PubMed Web of Science ®Google Scholar
• Gong EJ, Yun S-C, Jung H-Y, et al. Meta-analysis of first-line triple therapy for Helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci. 2014;29(5):704. doi: 10.3346/jkms.2014.29.5.704
   PubMed Web of Science ®Google Scholar
• Liu L, Nahata MC. Treatment of Helicobacter pylori infection in patients with penicillin allergy. Antibiotics. 2023;12(4):737. doi: 10.3390/antibiotics12040737
   Google Scholar
• Gisbert JP, Barrio J, Modolell I, et al. Helicobacter Pylori first-line and Rescue Treatments in the presence of penicillin allergy. Dig Dis Sci. 2015;60(2):458–464. doi: 10.1007/s10620-014-3365-2
   PubMed Web of Science ®Google Scholar
• Nyssen OP, Pérez‐Aisa Á, Tepes B, et al. Helicobacter pylori first‐line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp‐EuReg). Helicobacter. 2020;25(3):25. doi: 10.1111/hel.12686
   Web of Science ®Google Scholar
• Gebeyehu E, Nigatu D, Engidawork E, et al. Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: prospective follow up study. PloS One. 2019;14(11):e0225585. doi: 10.1371/journal.pone.0225585
   PubMed Web of Science ®Google Scholar
• Gatta L, Nyssen OP, Fiorini G, et al. Effectiveness of first and second-line empirical treatment in Italy: results of the European registry on Helicobacter pylori management. United Eur Gastroenterol J. 2023;11(1):103–113. doi: 10.1002/ueg2.12348
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Joshita S, Yamamoto C, et al. Efficacy and safety of eradication therapy for elderly patients with helicobacter pylori infection. Medicine. 2019;98(30):e16619. doi: 10.1097/MD.0000000000016619
   PubMed Web of Science ®Google Scholar
• Ono S, Kato M, Nakagawa S, et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017;22(3):e12374. doi: 10.1111/hel.12374
   Web of Science ®Google Scholar
• Alomar MJ. Factors affecting the development of adverse drug reactions (review article). Saudi Pharm J. 2014;22(2):83–94. doi: 10.1016/j.jsps.2013.02.003
   PubMed Web of Science ®Google Scholar
• Wang J, Cao Y, He W, et al. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine. 2021;100(51):e28323. doi: 10.1097/MD.0000000000028323
   PubMed Web of Science ®Google Scholar
• Liou J-M, Chen C-C, Chang C-M, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19(10):1109–1120. doi: 10.1016/S1473-3099(19)30272-5
   PubMed Web of Science ®Google Scholar
• Zagari RM, Romiti A, Ierardi E, et al. The “three-in-one” formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: efficacy and safety in daily clinical practice. Helicobacter. 2018;23(4):e12502. doi: 10.1111/hel.12502
   PubMed Web of Science ®Google Scholar
• Mesquita A, Rocha-Castro C, Guimarães D, et al. Multicentric study to assess Helicobacter pylori incidence, patient reported adverse events, compliance and effectiveness, in real-world setting. Int J Environ Res Public Health. 2022;19(19):12847. doi: 10.3390/ijerph191912847
   PubMed Web of Science ®Google Scholar
• Chen M-J, Chen C-C, Chen Y-N, et al. Systematic review with meta-analysis: concomitant therapy vs. Triple therapy for the first-line treatment of Helicobacter pylori infection. Am J Gastroenterol. 2018;113(10):1444–1457. doi: 10.1038/s41395-018-0217-2
   PubMed Web of Science ®Google Scholar
• Yeo YH, Hsu C-C, Lee C-C, et al. Systematic review and network meta-analysis: comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol. 2019;34(1):59–67. doi: 10.1111/jgh.14462
   PubMed Web of Science ®Google Scholar
• Graham DY, Canaan Y, Maher J, et al. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori eradication. Ann Intern Med. 2020;172(12):795–802. doi: 10.7326/M19-3734
   PubMed Web of Science ®Google Scholar
• Gisbert JP. Rifabutin for the Treatment of Helicobacter pylori Infection: A Review. Pathogens. 2020;10(1):15. doi: 10.3390/pathogens10010015
   PubMed Web of Science ®Google Scholar
• Dang Y, Reinhardt JD, Zhou X, et al. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One. 2014;9(11):e111030. doi: 10.1371/journal.pone.0111030
   PubMed Web of Science ®Google Scholar
• Penumetcha SS, Ahluwalia S, Irfan R, et al. The Efficacy of Probiotics in the management of Helicobacter Pylori: asystematic review. Cureus. 2021. doi:10.7759/cureus.20483
   Web of Science ®Google Scholar
• Shi X, Zhang J, Mo L, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori. Medicine. 2019;98(15):e15180. doi: 10.1097/MD.0000000000015180
   PubMed Web of Science ®Google Scholar
• Zhang M-M. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345. doi: 10.3748/wjg.v21.i14.4345
   PubMed Web of Science ®Google Scholar
• Zhu R, Chen K, Zheng Y-Y, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol. 2014;20(47):18013–18021. doi: 10.3748/wjg.v20.i47.18013
   PubMed Web of Science ®Google Scholar
• McFarland LV, Huang Y, Wang L, et al. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroenterol J. 2016;4:546–561.
   PubMed Web of Science ®Google Scholar
• Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069–1079. doi: 10.1111/j.1365-2036.2010.04457.x
   PubMed Web of Science ®Google Scholar
• Yu M, Zhang R, Ni P, Del Campo R, et al. Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: a meta-analysis of randomized controlled trials. PLoS One. 2019;14(10):e0223309. doi: 10.1371/journal.pone.0223309
   PubMed Web of Science ®Google Scholar
• Chen L, Xu W, Lee A, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine. 2018;35:87–96. doi: 10.1016/j.ebiom.2018.08.028
   PubMed Web of Science ®Google Scholar
• Viazis N, Argyriou K, Kotzampassi K, et al. A four-probiotics regimen combined with a standard Helicobacter pylori-eradication treatment reduces side effects and increases eradication rates. Nutrients. 2022;14(3):632. doi: 10.3390/nu14030632
   PubMed Web of Science ®Google Scholar
• Yasar B, Abu E, Kayadibi H, et al. Efficacy of probiotics in Helicobacter pylori eradication therapy. Turk J Gastroenterol. 2010;21(3):212–217. doi: 10.4318/tjg.2010.0090
   PubMed Web of Science ®Google Scholar
• Prast-Nielsen S, McNicholl A, O’Morain C. Comparison of the impact of Helicobacter pylori eradication treatment with bismuth and non-bismuth quadruple regimens on the gut microbiota. Microb Health Dis [Internet]. 2019;1:e145. [cited 2023 Sep 3]; Available from: https://www.microbiotajournal.com/wp-content/uploads/sites/7/2020/01/e145-Comparison-of-the-impact-of-Helicobacter-pylori-eradication-treatment-with-bismuth-and-non-bismuth-quadruple-regimens-on-the-gut-microbiota.pdf
   Google Scholar
• Nwokolo CU. Plasma ghrelin following cure of Helicobacter pylori. Gut. 2003;52(5):637–640. doi: 10.1136/gut.52.5.637
   PubMed Web of Science ®Google Scholar
• Lee M, Kemp JA, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999;159(19):159. doi: 10.1001/archinte.159.19.2312
   Google Scholar
• Nyssen OP, Vaira D, Tepes B, et al. Room for improvement in the treatment of Helicobacter pylori infection. J Clin Gastroenterol. 2022;56(2):e98–e108. doi: 10.1097/MCG.0000000000001482
   PubMed Web of Science ®Google Scholar
• Sue S, Suzuki N, Shibata W, et al. First-line helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin. Gastroenterol Res Pract. 2017;2017:1–6. doi: 10.1155/2017/2019802
   Web of Science ®Google Scholar